Enoxaparin sodium is a subcutaneously (SC) administered low-molecular-weight heparin approved in the United States for the inpatient or outpatient treatment of deep venous thrombosis (DVT) in place of ...
December 30, 2011 (Boston, MA) — Longer survival should not necessarily be expected from the use of preventive low-molecular-weight heparin (LMWH) in patients hospitalized with heart failure or other ...
The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment. Nineteen premature and ...
SILVER SPRING, Md. The Food and Drug Administration has approved the first generic version of a Sanofi-Aventis injected drug used to treat deep vein thrombosis, the agency said Friday. The FDA ...
A California biotechnology company won Food and Drug Administration permission Monday to sell a generic version of the blockbuster blood thinner Lovenox, following a years-long battle that was ...
LONDON, March 5 (Reuters) - Pfizer and Bristol-Myers Squibb's anti-clotting pill apixaban proved better than standard treatment Lovenox in a late-stage knee surgery trial, boosting prospects for the ...
LONDON, June 5 (Reuters) - Doctors in Europe can continue to use Sanofi-Aventis SA's heparin medicine Lovenox, despite low levels of contamination found in some batches of the product, the European ...
A total of 15 pregnant subjects on therapeutic doses of enoxaparin (1 mg/kg ±20% subcutaneously (s.c.) twice daily (b.i.d.)) were enrolled prospectively in this cross-sectional pilot project. Three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results